Downregulation of Gnas, Got2 and Snord32a Following Tenofovir Exposure of Primary Osteoclasts

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2009 Dec 23

PMID 20026012

Citations 21

Authors

Iwen F Grigsby

Lan Pham

Raj Gopalakrishnan

Louis M Mansky

Kim C Mansky

Affiliations

Soon will be listed here.

Abstract

Clinical observations have implicated the antiretroviral drug tenofovir with bone density loss during the management of HIV infection. The goal of this study was to investigate the in vitro effects of tenofovir exposure of primary osteoclasts in order to gain insights into the potential mechanisms for the drug-induced bone density loss. We hypothesized that tenofovir may alter the expression of key genes involved in osteoclast function. To test this, primary osteoclasts were exposed to physiologically relevant concentrations of the prodrug tenofovir disoproxil fumarate (TDF), then intensive microarray analysis was done to compare tenofovir-treated versus untreated cells. Specific downregulation of Gnas, Got2 and Snord32a were observed in the TDF-treated cells. The functions of these genes help to explain the basis for tenofovir-associated bone density loss. Our studies represent the first analysis of the effects of tenofovir on osteoclast gene expression and help to explain the basis of tenofovir-associated bone density loss in HIV-infected individuals.

Citing Articles

Analysis of the efficacy of drilling decompression autologous bone marrow and allogeneic bone grafting in the treatment of HIV-positive patients with early osteonecrosis of the femoral head.

Li S, Wang J, Ma R, Zhao C, Gao Z, Quan X BMC Musculoskelet Disord. 2023; 24(1):902.

PMID: 37990216 PMC: 10661564. DOI: 10.1186/s12891-023-07039-9.

The emerging role of snoRNAs in human disease.

Zhang X, Wang C, Xia S, Xiao F, Peng J, Gao Y Genes Dis. 2023; 10(5):2064-2081.

PMID: 37492704 PMC: 10363644. DOI: 10.1016/j.gendis.2022.11.018.

MiRNAs and snoRNAs in Bone Metastasis: Functional Roles and Clinical Potential.

Puppo M, Jaafar M, Diaz J, Marcel V, Clezardin P Cancers (Basel). 2023; 15(1).

PMID: 36612237 PMC: 9818347. DOI: 10.3390/cancers15010242.

Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort.

Noe S, Heldwein S, Wiese C, Pascucci R, Von Krosigk A, Schabaz F Adv Pharmacol Sci. 2019; 2018:6069131.

PMID: 30687401 PMC: 6330833. DOI: 10.1155/2018/6069131.

Continued Interest and Controversy: Vitamin D in HIV.

Hsieh E, Yin M Curr HIV/AIDS Rep. 2018; 15(3):199-211.

PMID: 29713871 PMC: 6003869. DOI: 10.1007/s11904-018-0401-4.

References

HIGA S, Yoshihama M, Tanaka T, Kenmochi N . Gene organization and sequence of the region containing the ribosomal protein genes RPL13A and RPS11 in the human genome and conserved features in the mouse genome. Gene. 1999; 240(2):371-7. DOI: 10.1016/s0378-1119(99)00429-1. View

Boffito M, Pozniak A, Kearney B, Higgs C, Mathias A, Zhong L . Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob Agents Chemother. 2005; 49(10):4386-9. PMC: 1251521. DOI: 10.1128/AAC.49.10.4386-4389.2005. View

Desai V, Lee T, Delongchamp R, Leakey J, Lewis S, Lee F . Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver. Mitochondrion. 2008; 8(2):181-95. DOI: 10.1016/j.mito.2008.01.002. View

Cossarizza A, Moyle G . Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004; 18(2):137-51. DOI: 10.1097/00002030-200401230-00002. View

Mansky K, Sankar U, Han J, Ostrowski M . Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem. 2002; 277(13):11077-83. DOI: 10.1074/jbc.M111696200. View

Wactawski-Wende J, Grossi S, Trevisan M, Genco R, Tezal M, Dunford R . The role of osteopenia in oral bone loss and periodontal disease. J Periodontol. 1996; 67(10 Suppl):1076-84. DOI: 10.1902/jop.1996.67.10s.1076. View

Cihlar T, Birkus G, Greenwalt D, Hitchcock M . Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002; 54(1):37-45. DOI: 10.1016/s0166-3542(01)00210-8. View

Sakamoto A, Chen M, Nakamura T, Xie T, Karsenty G, Weinstein L . Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone. J Biol Chem. 2005; 280(22):21369-75. DOI: 10.1074/jbc.M500346200. View

Van Rompay K, Brignolo L, Meyer D, Jerome C, Tarara R, Spinner A . Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004; 48(5):1469-87. PMC: 400569. DOI: 10.1128/AAC.48.5.1469-1487.2004. View

10.

Purdy J, Gafni R, Reynolds J, Zeichner S, Hazra R . Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008; 152(4):582-4. PMC: 2390888. DOI: 10.1016/j.jpeds.2007.12.020. View

11.

Van Gelder R, von Zastrow M, Yool A, Dement W, Barchas J, Eberwine J . Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A. 1990; 87(5):1663-7. PMC: 53542. DOI: 10.1073/pnas.87.5.1663. View

12.

Moreau M, Guillet C, Massin P, Chevalier S, Gascan H, Basle M . Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol. 2006; 73(5):718-23. DOI: 10.1016/j.bcp.2006.09.031. View

13.

Mansky K, Sulzbacher S, Purdom G, Nelsen L, Hume D, Rehli M . The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter. J Leukoc Biol. 2002; 71(2):304-10. View

14.

Surendran S, Matalon K, Szucs S, Tyring S, Matalon R . Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease. J Child Neurol. 2003; 18(9):611-5. DOI: 10.1177/08830738030180090701. View

15.

Matera A, Terns R, Terns M . Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol. 2007; 8(3):209-20. DOI: 10.1038/nrm2124. View

16.

Kiss T . Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. 2001; 20(14):3617-22. PMC: 125535. DOI: 10.1093/emboj/20.14.3617. View

17.

Mansky K, Marfatia K, Purdom G, Luchin A, Hume D, Ostrowski M . The microphthalmia transcription factor (MITF) contains two N-terminal domains required for transactivation of osteoclast target promoters and rescue of mi mutant osteoclasts. J Leukoc Biol. 2002; 71(2):295-303. View

18.

Barditch-Crovo P, Deeks S, Collier A, Safrin S, Coakley D, Miller M . Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001; 45(10):2733-9. PMC: 90724. DOI: 10.1128/AAC.45.10.2733-2739.2001. View

19.

Gafni R, Hazra R, Reynolds J, Maldarelli F, Tullio A, DeCarlo E . Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006; 118(3):e711-8. DOI: 10.1542/peds.2005-2525. View

20.

Omer A, Lowe T, Russell A, Ebhardt H, Eddy S, Dennis P . Homologs of small nucleolar RNAs in Archaea. Science. 2000; 288(5465):517-22. DOI: 10.1126/science.288.5465.517. View